Inverness Medical and BG MEDICINE to Develop Galectin-3 Test for Inverness’ Triage® Meter - Gilde Healthcare

Inverness Medical and BG MEDICINE to Develop Galectin-3 Test for Inverness’ Triage® Meter

26 April 2010

Waltham, MA—BG Medicine, Inc. announced today that it has entered into an agreement with Inverness Medical Innovations, Inc. (NYSE: IMA)—a global leader in enabling individuals to take charge of their health at home through the merger of rapid diagnostics and health management—for the development and commercialization of a galectin-3 test for Inverness’ Triage Meter Pro. Galectin-3 is a novel biomarker that may play a role in detecting the development and progression of heart failure.

Under the agreement, Inverness will be responsible for the development of the test in accordance with certain plans and milestones, and Inverness and BG Medicine will collaborate in support of development of the test and regulatory filings.

“We look forward to the development of additional heart failure biomarker content, for use in conjunction with existing biomarkers, to enhance the assessment of this complex and costly medical condition,”

said Ron Zwanziger, President and CEO of Inverness.

“BNP and galectin-3 each provide important independent information about a patient’s heart failure.” said Pieter Muntendam, M.D., President and CEO of BG Medicine. “This business opportunity was created by the natural complementarity of the two tests.”

About Inverness Medical Innovations
By developing new capabilities in near-patient diagnosis, monitoring and health management, Inverness Medical Innovations enables individuals to take charge of improving their health and quality of life.  A global leader in rapid point-of-care diagnostics, Inverness’ products, as well as its new product development efforts, focus on infectious disease, cardiology, oncology, drugs of abuse and women’s health.  Inverness is headquartered in Waltham, Massachusetts.
 
About BG Medicine
BG Medicine is a life sciences company focused on the discovery, development, and commercialization of novel diagnostics based on biomarkers to improve patient outcomes and contain healthcare costs.

Gilde Healthcare portfolio company Nyxoah announces CE-mark approval to treat complete concentric collapse (CCC) patients

Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that DEKRA Notified Body has approved...
5 October 2021

Gilde Healthcare portfolio company Noema Pharma appoints Jeffrey Jonas as Independent Chairman of the Board of Directors

Noema Pharma, a Swiss-based clinical stage company targeting orphan central nervous system (CNS) diseases, today announces the appointment of Jeffrey Jonas MD as Chairman of the Board of Directors. Dr. Jonas is a neuropsychiatry expert...
4 October 2021

Gilde Healthcare company Acacia Pharma announces marketing authorization application for BARHEMSYS® in Europe

Acacia Pharma (EURONEXT: ACPH), a commercial stage biopharmaceutical company focused on developing and commercializing novel products to improve the care of patients undergoing serious medical treatments such as surgery, invasive procedures, or cancer chemotherapy, announces...
29 September 2021